Edwards Lifesciences (EW)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$94.82-0.38%
Close 2026-07-07 · 1-day change
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→QuarterlyIQ Insights · EW
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Approval of an amended and restated long-term stock incentive compensation program.
Chief Financial Officer (CFO) — Theodora Mistras: Edwards Lifesciences Corporation appointed Theodora Mistras as the new Corporate Vice President and Chief Financial Officer.
Results of Operations and Financial Condition. On April 23, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Results of Operations and Financial Condition. On February 10, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as a…
Other Events. On January 9, 2026 Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the United States District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the Company’s proposed acquisition of JenaValve Technology, Inc (“JenaValve”). As a result, the Company will not acquire JenaValve. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by referen…
CFO — Scott Ullem: The CFO is transitioning from his role by mid-year 2026, and the company is initiating a selection process for a new CFO.
Results of Operations and Financial Condition. On October 30, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as ame…
Other Events. On August 19, 2025, Edwards Lifesciences Corporation a Delaware corporation, issued a press release announcing its entry into an accelerated share repurchase agreement. A copy of the press release is filed as Exhibit 99.1, and is incorporated herein by reference.
Regulation FD Disclosure. On August 6, 2025, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the U.S. Federal Trade Commission has moved to block the Company’s proposed acquisition of JenaValve Technology, Inc. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed”…
Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart — Larry L. Wood: Mr. Wood resigned to accept a senior leadership position at another company.
Results of Operations and Financial Condition. On July 24, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Approval of amendments to stock purchase plans.
Results of Operations and Financial Condition. On April 23, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Results of Operations and Financial Condition. On February 11, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as a…
Results of Operations and Financial Condition. On October 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as ame…
Regulation FD Disclosure. On September 3, 2024, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the Company has completed its previously disclosed sale of the Company’s Critical Care product group to Becton, Dickinson and Company. In the same press release, the Company announced that its Board of Directors approved $1.5 billion of additional share repurchase authorization. Also in the same press release, the Company announced its entry into a $500 milli…
Results of Operations and Financial Condition. On July 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Other Events. In connection with the Company’s acquisition of JenaValve and Endotronix, the Company expects to pay a total upfront purchase price of approximately $1.2 billion in cash at the closing of these acquisitions, plus up to an additional $445 million upon the achievement of certain milestones. Each of the JenaValve and Endotronix acquisitions is subject to the satisfaction or waiver of certain closing conditions. Forward-Looking Statements This report includes forward-looking stateme…
Other Events. In connection with the Company’s acquisition of Innovalve, the Company expects to pay consideration of approximately $300 million in cash at the closing of the acquisition, which is expected to occur by the end of 2024. Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as “may,”…
Director — David T. Feinberg, M.D.: Dr. David T. Feinberg was appointed to the Board of Directors and will also serve on the Audit Committee.
Principal Accounting Officer — Robert W.A. Sellers: Mr. Robert W.A. Sellers is retiring as Principal Accounting Officer, and Mr. Andrew M. Dahl will succeed him.
Regulation FD Disclosure. On June 3, 2024, Edwards Lifesciences Corporation (the “Company”) issued a press release announcing the Company entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Becton, Dickinson and Company (“Purchaser”), pursuant to which Purchaser has agreed to acquire the Company’s Critical Care product group (the “Business”) for $4,200,000,000 in cash (the “Transaction”). A copy of the press release is attached as Exhibit 99.1 and is incorporated…
Other Events. Also on June 3, 2024, in connection with the Company’s entry into the Purchase Agreement, the Company announced that it is no longer pursuing the previously announced spin-off of the Business. Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticip…
Results of Operations and Financial Condition. On April 25, 2024, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Non-Executive Chairman — Michael A. Mussallem: Michael A. Mussallem is retiring as Non-Executive Chairman and will be succeeded by Nicholas J. Valeriani.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.